Seems like NAD boosters (NMN, NR, etc.) may not be so helpful in the quest to maintain brain function and cardiovascular health (though I’m unsure of the influence of the APOE knockout status of the mice used in the study and how that translates to human issues).
https://www.atherosclerosis-journal.com/article/S0021-9150(25)00086-3/fulltext
The general increase in inflammatory markers is a more broader concern of NR supplementation and one would assume this would apply for NMN as well.
Charles Brenner has (unsurprisingly) waded in on this.
https://www.twitter.com/CharlesMBrenner/status/1910526936662552764
“obviously 8 completed human clinical trials showing anti-inflammatory effects of NR in ppl are more convincing than an experiment in a mutant mouse strain”
It is all part of this question as to whether you can have two much of a B3 vitamer, whether this relates to all of them or only a limited subset.
Just sharing what arrived in my inbox.
Since that discovery of a blood biomarker for Alzheimer’s disease, there has been remarkable further advances, including the availability of the test over the past year at a cost of approximately $200.
Not a crazy price
In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease pathology with remarkable accuracy (see Part 7 of this series). How about in the general population? Could these tests catch people in the early stages of AD, before they turn up at their doctor with memory concerns?
What did they find? Schöll shared some hot-off-the-press data. “We’ve only had it a few days, so it is very preliminary,” he told the audience in Vienna. Still, some patterns may be emerging. The neotiv neotiv | Enabling cognitive health cognitive test appears to correlate with age, with older people scoring lower. Men performed worse than women across all ages; though the difference was slight, it was consistent, said Schöll.
Intriguingly, plasma p-tau217 rose with age, and more so among people who tested positive for amyloid. This was slightly different than Sebastian Palmqvist, Lund University, reported for primary care settings. There too, the marker inched up with age in people who were amyloid-negative, but the opposite was true among the amyloid-positives (see Part 7 of this series). In REAL AD, baseline numbers were slightly higher in people who carried an ApoE4 allele.
https://www.alzforum.org/news/conference-coverage/blood-tests-not-just-impaired
